
-
Kronos Bio NasdaqCM:KRON Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Location: 1300 So. El Camino Real, San Mateo, CA, 94402, United States | Website: https://www.kronosbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-34.7M
Cash
99.73M
Avg Qtr Burn
-13.59M
Short % of Float
1.25%
Insider Ownership
24.31%
Institutional Own.
31.44%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KB-9558 Details Multiple myeloma | Phase 1 Update | |
Lanraplenib +gilteritinib Details Leukemia, Blood cancer, Acute myeloid leukemia, Cancer | Failed Discontinued | |
Entospletinib Details HOXA9/MEIS1-high AML (Acute myeloid leukemia) | Failed Discontinued | |
Failed Discontinued |